ASP Isotopes Inc. Common Stock logo

ASP Isotopes Inc. Common Stock(ASPI)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.74
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ASPI

11/13/2026: ASPI (1-star) is currently NOT-A-BUY. Pass it for now.

ASP Isotopes Inc. is an advanced materials company that develops proprietary enrichment technologies to produce high-value isotopes for nuclear medicine, advanced nuclear fuels, and high-tech industries. The company's main strengths lie in its innovative Aerodynamic Separation Process and Quantum Enrichment platforms, which target high-growth clean energy and healthcare sectors. Its primary investment story centers on capturing long-term demand for specialized nuclear fuels like HALEU and medical isotopes. However, the company faces notable risks, including ongoing operating cash burn, pre-commercial scaling hurdles, and execution uncertainties. The stock suits growth-oriented investors willing to accept high volatility in exchange for exposure to critical nuclear infrastructure development.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers high-growth exposure to emerging nuclear energy and medical isotope markets.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp price movements driven by operational headlines and sector sentiment.
Value investorWeak fitUnprofitable operations and early-stage financials make it unsuitable for traditional value strategies.
Dividend investorWeak fitThe company pays no dividends as it prioritizes capital reinvestment into R&D and scaling.
Low-risk investorWeak fitHigh volatility, execution risks, and pre-commercial cash burn create substantial risk exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap advanced materials stocks frequently experience sharp valuation swings.
Valuation riskMedium / highPricing relies heavily on long-term future growth assumptions rather than current earnings.
Competition risk (nuclear fuel and isotope processing)Medium / highEstablished players and well-funded rivals compete for market share in specialized materials.
Business qualityMediumProprietary technology provides a strong moat, but commercial validation is still underway.
Dividend incomeLow / noneNo payouts are offered, meaning total return depends entirely on capital appreciation.
Execution riskHighSuccessful scaling of novel enrichment plants is critical to achieving financial self-sufficiency.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 266.76M USD
Price to earnings Ratio -
1Y Target Price 13
Price to earnings Ratio -
1Y Target Price 13
Volume (30-day avg) 4.3M shares
Beta 3.79
52 Weeks Range 1.66 - 8.60
Updated Date 11/15/2026
52 Weeks Range 1.66 - 8.60
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.49

Sector & Industry Intelligence

Sector

Basic Materials

Defensive
Sentiment
Bearish
Momentum
Momentum Steady
BUY participation
23.1%
Active BUY / eligible
9 / 39
30-Day BUY Count Change
+2
Market state
Bearish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Specialty Chemicals

BUY participation
57.1%
Active BUY / eligible
4 / 7
30-Day BUY Count Change
+1

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 75.55%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ASPI receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
ASPI has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and strong ownership. In FY2025 versus FY2024, strong revenue growth (+475.5%) is partially offset by negative earnings growth (-441.5%), weak cash generation (FCF margin -198.9%), weak profitability (net margin -734.2%).

Financial Health Rating

★★★★★
ASPI's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 73.7%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is ASPI's strongest growth driver at +475.5% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-441.5%, negative) and free-cash-flow growth (-69.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 45.7% and approximately 86.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 14.49% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 6.01%
Encompass Capital Advisors LLC 4.28%
Vanguard Capital Management, LLC 3.25%
Rovida Investment Management Ltd 2.67%
UBS Group AG 2.12%

Unit Economics (Per $1K Revenue)

★★★★★
ASPI generates approximately $143 of gross profit, $-2,398 of operating income, and $-1,989 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.18% (Tax Credit)

Quantitative Style Profile

★★★★★
ASPI has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Specialist Isotopes and Related ServicesProduction and sale of high-value, low-volume isotopes like Molybdenum-100 and Carbon-14 for medical and industrial customers.Provides immediate commercial revenue streams from niche healthcare and technology applications.
Nuclear Fuels SegmentResearch, development, and upcoming supply contracts for HALEU and Lithium-6 directed at advanced nuclear reactors.Represents the long-term high-growth narrative centered on clean energy infrastructure.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 54.35
Enterprise Value 280.64M
Price to Sales(TTM) 8.65
Enterprise Value 280.64M
Price to Sales(TTM) 8.65
Enterprise Value to Revenue 9.1
Enterprise Value to EBITDA -12.17
Shares Outstanding 153.31M
Shares Floating 133.05M
Shares Outstanding 153.31M
Shares Floating 133.05M
Percent Insiders 14.49
Percent Institutions 45.67

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.